Cite
Co-morbidities and co-medications as confounders of cardioprotection-Does it matter in the clinical setting?
MLA
Kleinbongard, Petra, et al. “Co-Morbidities and Co-Medications as Confounders of Cardioprotection-Does It Matter in the Clinical Setting?” British Journal of Pharmacology, vol. 177, no. 23, Dec. 2020, pp. 5252–69. EBSCOhost, https://doi.org/10.1111/bph.14839.
APA
Kleinbongard, P., Bøtker, H. E., Ovize, M., Hausenloy, D. J., & Heusch, G. (2020). Co-morbidities and co-medications as confounders of cardioprotection-Does it matter in the clinical setting? British Journal of Pharmacology, 177(23), 5252–5269. https://doi.org/10.1111/bph.14839
Chicago
Kleinbongard, Petra, Hans Erik Bøtker, Michel Ovize, Derek J Hausenloy, and Gerd Heusch. 2020. “Co-Morbidities and Co-Medications as Confounders of Cardioprotection-Does It Matter in the Clinical Setting?” British Journal of Pharmacology 177 (23): 5252–69. doi:10.1111/bph.14839.